Research Alert: CFRA Retains Hold View On Shares Of Johnson & Johnson

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We cut our target to $156 from $165, 13.

MT Newswires10minutes ago

WHO Considering Safety Alert on Kenvue Kids Cough Syrup

Seeking Alpha11minutes ago

How Is The Market Feeling About Intra-Cellular Therapies?

Intra-Cellular Therapies's (NYSE:ITCI) short percent of float has risen 4.8% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 4.15% of all regu

Benzinga12:00 ET

Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges

Drug shortages in the UK have more than doubled between 2020 and 2023, a recent study by the Nuffield Trust reveals. Brexit is cited as a significant factor exacerbating the country's struggle to mana

BenzingaApr 19 11:39 ET

Pinning Down Pfizer Inc.'s (NYSE:PFE) P/S Is Difficult Right Now

With a median price-to-sales (or "P/S") ratio of close to 2.8x in the Pharmaceuticals industry in the United States, you could be forgiven for feeling indifferent about Pfizer Inc.'s (NYSE:PFE) P/S r

Simply Wall StApr 19 11:04 ET

Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals

Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve

BenzingaApr 19 11:00 ET